How Five Year Eczema Drug Data Will Impact Almirall Stock Investors
- Almirall reported long-term Phase 3b ADlong data for lebrikizumab in moderate-to-severe atopic dermatitis, with 108-week results presented at the 35th EADV Congress in Vienna. The data included sustained EASI, IGA and itch outcomes, along with a consistent safety profile without new safety signals.
- The ADlong extension builds on prior AD trials and provides up to 5 years of continuous lebrikizumab exposure. This reinforces Almirall’s focus on chronic dermatology treatments that may support demand durability and portfolio depth in atopic dermatitis.
- The next area of attention is how Almirall's investment narrative could be shaped by sustained five-year lebrikizumab efficacy data.
Almirall Investment Narrative Recap
To own Almirall, you need to believe in a focused dermatology story in which a few high-impact drugs, including Ebglyss, support a growing portfolio of chronic skin treatments. The recent ADlong lebrikizumab data mainly reinforces the long-term treatment narrative rather than changing the near term picture. The key near term catalyst still lies in execution on launches and uptake across Europe.
The biggest risk remains product concentration and pricing pressure on high cost biologics in atopic dermatitis and psoriasis. ADlong’s five year exposure data does not remove that risk, but it may help Almirall defend Ebglyss clinically against rival IL 13 or broader immunology agents if payers or dermatologists start to scrutinise durability and safety more closely.
The most relevant announcement for this catalyst is the late breaking ADlong readout at EADV 2026. Those 108 week data points on EASI, IGA and itch, along with the reported absence of new safety signals, help support Ebglyss as a chronic use biologic for moderate to severe atopic dermatitis in eligible adults and adolescents.
For investors, this contributes to the core thesis that Almirall’s dermatology platform can support its R&D spend and justify concentration in a few flagship assets. The operational test now is whether this evidence translates into stable prescribing, formulary support and limited need for rescue therapies, while the business manages biologic cost of goods and avoids margin pressure from payers.
Almirall Consensus Forecasts and Valuation Setup
Almirall's analyst narrative points to revenues of €1.5b and earnings of €165.2 million by 2029, built on assumed yearly top line expansion of 10.5% and an earnings step up of about €125 million from €39.9 million today.
Uncover why Almirall's fair value indicates a 45% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
One alternate view hangs on an upside catalyst. The most optimistic analysts were already pencilling in €1.6b of revenue and €195.9 million of earnings by 2029 for Almirall before this ADlong update landed. You might see this fresh data and wonder if those already upbeat assumptions now look too cautious or too bold.
Explore 2 other Almirall fair value estimates, including one that suggests potential upside of up to 89% from the current price.
Reach Your Own Conclusion
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Almirall research is our analysis highlighting 4 key rewards that could impact your investment decision.
- See our latest analysis for Almirall. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Almirall's overall financial health at a glance.
Looking for more Almirall-sized investment ideas?
Once you have a view on Almirall, it can help to compare it with other businesses that fit different risk, income, or balance sheet profiles using the Simply Wall St Screener.
- For investors who care most about capital strength and resilience, start with a list of solid balance sheet and fundamentals (204 results) that can help you focus on companies with room to absorb shocks.
- If you prefer steadier profiles and aim to limit volatility, consider a 222 resilient stocks with low risk scores that narrows the field to businesses with more measured risk scores.
- Those hunting for under-the-radar opportunities can scan a 618 high quality undiscovered gems and see which stocks pair quieter coverage with strong fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com